Cholestagel ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
96Crohn disease2

96. Crohn disease


Clinical trials : 2,400 Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-010727-91-DE
(EUCTR)
01/03/201105/06/2012Colesevelam, which is a medication which binds bile acid, to test in patients with Crohns diseaseColesevelam for the treatment of bile acid malabsorption in patients with Crohn’s disease (Colesevelam für die Therapie der Gallensäuren-Malabsorption bei M. Crohn-Patienten) Morbus Crohn
MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders
Trade Name: Cholestagel
Product Name: Cholestagel
Product Code: EU/1/03/268/002
INN or Proposed INN: Colesevelam
LMU München, Campus GroßhadernNULLNot RecruitingFemale: yes
Male: yes
Germany
2EUCTR2009-010163-16-GB
(EUCTR)
05/06/200918/08/2009Bile salt manipulation as a novel treatment for Crohn’s disease: a single centre open label pilot study of atorvastatin and colesevalam in patients with active ileal Crohn’s disease - Bile salt manipulation in Crohn’s diseaseBile salt manipulation as a novel treatment for Crohn’s disease: a single centre open label pilot study of atorvastatin and colesevalam in patients with active ileal Crohn’s disease - Bile salt manipulation in Crohn’s disease Active Crohn's disease affecting the ileum
MedDRA version: 9.1;Level: LLT;Classification code 10011406;Term: Crohn's ileitis
MedDRA version: 9.1;Classification code 10058815;Term: Crohn's disease acute episode
Trade Name: Lipitor
Trade Name: Cholestagel
University College LondonNULLNot Recruiting Female: yes
Male: yes
13 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom